Systemic Therapy for Colon Cancer

Gastroenterology Clinics of North America

Volumn 37, Issue 1, 2008, Pages 287-295

  Asmis, Timothy R ^a   Saltz, Leonard ^a,b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PANITUMUMAB;

ACUTE DIARRHEA; ALOPECIA; ARTERY THROMBOSIS; BONE MARROW SUPPRESSION; CANCER MORTALITY; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER SCREENING; CANCER STAGING; CANCER SURGERY; CANCER THERAPY; CARCINOGENESIS; CLINICAL EVALUATION; CLINICAL FEATURE; CLINICAL TRIAL; COLON CANCER; COMPREHENSION; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; FATIGUE; GASTROENTEROLOGY; HAND FOOT SYNDROME; HUMAN; HYPERSENSITIVITY; HYPERTENSION; HYPOMAGNESEMIA; IMMUNE RESPONSE; LIVER METASTASIS; LUNG METASTASIS; MORBIDITY; NAUSEA; NEUROTOXICITY; NUTRITIONAL STATUS; ONCOLOGY; OVARY METASTASIS; PARESTHESIA; PATHOLOGIST; PATIENT CARE; PERIPHERAL NEUROPATHY; PERITONEUM METASTASIS; PHYSICIAN; POPULATION; POSTOPERATIVE CARE; PRIMARY MEDICAL CARE; RADIOLOGIST; RASH; RETROPERITONEAL CANCER; REVIEW; RISK FACTOR; SURGEON; UNITED STATES; WOUND HEALING IMPAIRMENT;

COLONIC NEOPLASMS; COMBINED MODALITY THERAPY; HUMANS; TREATMENT OUTCOME;

EID: 39749175272     PISSN: 08898553     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.gtc.2007.12.005     Document Type: Review

References (27)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2006. CA Cancer J Clin 56 2 (2006) 106-130
2. Canadian cancer statistics (2006), Health Statistics Division, Stastics. Canada, Ottawa (Ontario). http://www.cancer.ca/ccs/internet/standard/0,3182,3596_316704__langId-en ,00.html Accessed January 22, 2008
3. Guillem J.G., Wood W.C., Moley J.F., et al. ASCO/SSO review of current role of risk-reducing surgery in common hereditary cancer syndromes. J Clin Oncol 24 28 (2006) 4642-4660
4. Peltomaki P. Role of DNA mismatch repair defects in the pathogenesis of human cancer. J Clin Oncol 21 6 (2003) 1174-1179
5. Terry P., Giovannucci E., Michels K.B., et al. Fruit, vegetables, dietary fiber, and risk of colorectal cancer. J Natl Cancer Inst 93 7 (2001) 525-533
6. Chao A., Thun M.J., Connell C.J., et al. Meat consumption and risk of colorectal cancer. JAMA 293 2 (2005) 172-182
7. Chlebowski R.T., Wactawski-Wende J., Ritenbaugh C., et al. Estrogen plus progestin and colorectal cancer in postmenopausal women. N Engl J Med 350 10 (2004) 991-1004
8. Winawer S.J., Zauber A.G., Ho M.N., et al. Prevention of colorectal cancer by colonoscopic polypectomy. The National Polyp Study Workgroup. N Engl J Med 329 27 (1993) 1977-1981
9. Winawer S., Fletcher R., Rex D., et al. Colorectal cancer screening and surveillance: clinical guidelines and rationale-update based on new evidence. Gastroenterology 124 2 (2003) 544-560
10. Seeff L.C., Manninen D.L., Dong F.B., et al. Is there endoscopic capacity to provide colorectal cancer screening to the unscreened population in the United States?. Gastroenterology 127 6 (2004) 1661-1669
11. Rabeneck L., and Paszat L.F. A population-based estimate of the extent of colorectal cancer screening in Ontario. Am J Gastroenterol 99 6 (2004) 1141-1144
12. Vinden C., Schultz S., and Rabeneck L. Use of large bowel procedures in Ontario: an ICES Research atlas (2004), Institute for clinical evaluative sciences. Available at: http://www.ices.on.ca/webpage.cfm?site_id=1&org_id=67&morg_id=0 &gsec_id=0&item_id=1947&type=atlas
13. Desch C.E., Benson III A.B., Somerfield M.R., et al. Colorectal cancer surveillance: 2005 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol 23 33 (2005) 8512-8519
14. Giovannucci E., and Michaud D. The role of obesity and related metabolic disturbances in cancers of the colon, prostate, and pancreas. Gastroenterology 132 6 (2007) 2208-2225
15. Meyerhardt JA, Niedzwiecki D, Hollis D, et al. The impact of dietary patterns on cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803. [abstract 4019]. Presented at the ASCO Annual Meeting. Chicago; June 1-4, 2007.
16. Tinmouth J., Tomlinson G., Dalibon N., et al. A comparison of laparoscopically assisted and open colectomy for colon cancer. N Engl J Med 350 20 (2004) 2050-2059
17. Fong Y., Cohen A.M., Fortner J.G., et al. Liver resection for colorectal metastases. J Clin Oncol 15 3 (1997) 938-946
18. Andre T., Boni C., Mounedji-Boudiaf L., et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350 23 (2004) 2343-2351
19. Therasse P., Arbuck S.G., Eisenhauer E.A., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92 3 (2000) 205-216
20. Krueger G.M., Alexander L.L., Whippen D.A., et al. Arnoldus Goudsmit, MD, PhD: chemotherapist, visionary, founder of the American Society of Clinical Oncology, 1909-2005. J Clin Oncol 24 24 (2006) 4033-4036
21. Tournigand C., Andre T., Achille E., et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 22 2 (2004) 229-237
22. Colucci G., Gebbia V., Paoletti G., et al. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. J Clin Oncol 23 22 (2005) 4866-4875
23. Hurwitz H., Fehrenbacher L., Novotny W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350 23 (2004) 2335-2342
24. Saltz L., Clarke S., Diaz-Rubio E., et al. Bevacizumab (Bev) in combination with XELOX or FOLFOX4: efficacy results from XELOX-1/NO16966, a randomized phase III trial in the first-line treatment of metastatic colorectal cancer (MCRC). Gastrointestinal Cancers Symposium (2007), ASCO, Orlando
25. Saltz L.B., Meropol N.J., Loehrer Sr. P.J., et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 22 7 (2004) 1201-1208
26. Cunningham D., Humblet Y., Siena S., et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351 4 (2004) 337-345
27. Van Cutsem E., Peeters M., Siena S., et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 25 (2007) 1658-1664